Investing
Proceeds from restricted investments
Year-over-year, this metric was flat by 0.0%, from $48.83M to $48.83M. Over 2 years (FY 2021 to FY 2025), Proceeds from restricted investments shows an upward trend with a 19.3% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
First reportedQ1 2017
Last reportedQ1 2026Apr 30, 2026
Metric ID:
investing_proceeds_from_sale_of_restricted_investmentsHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $15.33M | $16M | $9.4M | $14.83M | $65.73M | $0 | $49.23M | $9.25M | $39.98M | $17.9M | $48.83M | $9.25M | $1.7M | $0 | $48.83M |
| QoQ Change | — | — | +4.4% | -41.3% | +57.7% | +343.3% | -100.0% | — | -81.2% | +332.2% | -55.2% | +172.8% | -81.1% | -81.6% | -100.0% | — |
| YoY Change | — | — | — | — | — | +328.9% | -100.0% | +423.7% | -37.6% | -18.8% | +93.5% | +22.1% | -48.3% | — | — | +0.0% |
Range$0 – $65.73M
Avg YoY Growth+73.7%
Median YoY Growth+0.0%
Proceeds from restricted investments at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's proceeds from restricted investments?
- Alnylam Pharmaceuticals (ALNY) reported proceeds from restricted investments of $48.83M in Q1 2026.
- How has Alnylam Pharmaceuticals's proceeds from restricted investments changed year-over-year?
- Alnylam Pharmaceuticals's proceeds from restricted investments decreased by 0.0% year-over-year, from $48.83M to $48.83M.
- What is the long-term trend for Alnylam Pharmaceuticals's proceeds from restricted investments?
- Over 2 years (2021 to 2025), Alnylam Pharmaceuticals's proceeds from restricted investments has grown at a 19.3% compound annual growth rate (CAGR), from $41.98M to $59.78M.